SynthesisBMC ophthalmology2026
Efficacy of topical nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of diabetic macular edema (DME): a systematic review and meta-analysis.
Synthesis in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the efficacy of topical nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with Diabetic Macular Edema (DME).
methodsA systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic databases, including MEDLINE, EMBASE, PubMED, CINAHL, and the Cochrane Central Register of Controlled Trials (CENTRAL), were comprehensively searched for relevant studies published by December 2023 using key words such as 'diabetic macular edema', 'topical NSAIDS', and 'anti-VEGF'. All studies focusing on the treatment diabetic macular edema using NSAIDS versus anti-VEGF were considered, including interventional, observational, pilot, and randomized controlled trials, and the data from the selected studies were pooled for analysis. The primary outcome measured was best-corrected visual acuity (BCVA), while secondary outcomes included central macular thickness (CMT), macular volume, and complications.
resultsSix studies, with a total sample size of 446 patients and 892 eyes, were included. The findings showed a statistically significant improvement in BCVA favoring the NSAIDs group (mean difference: 1.82, 95% CI: 0.12 to 3.53) with moderate heterogeneity (I^2 = 60%, P = 0.08). CMT showed a favorable trend towards the NSAIDs group with a mean difference of 51.84 μm (95% CI: -15.23 to 118.91), although this was not statistically significant, with high heterogeneity (I^2 = 91%, P < 0.0001). Macular volume analysis showed no statistically significant difference in macular volume between the groups (mean difference: 0.29, 95% CI: -0.36 to 0.95), with high heterogeneity observed (I^2 = 77%, P = 0.04).
conclusionThis study showed that topical NSAIDs, alone or combined with anti-VEGF therapy significantly improved BCVA; however, the reduction in CMT was not significant. Evidence for macular volume reduction remains insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.